APA (7th ed.) Citation

Ma, L., Zheng, R., Xu, L., Zhu, Y., Yin, H., Zhang, X., . . . Zha, X. (2026). Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer. Cancer Research & Treatment, 58(2), 501. https://doi.org/10.4143/crt.2024.1200

Chicago Style (17th ed.) Citation

Ma, Lingjun, Ran Zheng, Lingyun Xu, Ying Zhu, Hong Yin, Xiaoqing Zhang, Rong Deng, Jue Wang, and Xiaoming Zha. "Differences in Responses to Neoadjuvant Anti-HER2 Therapy Between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer." Cancer Research & Treatment 58, no. 2 (2026): 501. https://doi.org/10.4143/crt.2024.1200.

MLA (9th ed.) Citation

Ma, Lingjun, et al. "Differences in Responses to Neoadjuvant Anti-HER2 Therapy Between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer." Cancer Research & Treatment, vol. 58, no. 2, 2026, p. 501, https://doi.org/10.4143/crt.2024.1200.